Beyond the Label

12.17.13 | By

Last week, I had the opportunity to participate in a panel discussion at the Elsevier Business Intelligence FDA/CMS Summit entitled, “Beyond the Label.” 

Information Exchange

12.16.13 | By

PhRMA Pushes Back on New York Times

A Fully Collaborative and Informed Ecosystem

12.16.13 | By

Worth a read are the commentaries surrounding the latest Room for Debate question posed by the New York Times; it’s a good snapshot into the various views on the issue of biopharmaceutical and physician interaction. Our CEO, John Castellani, joined five other health care leaders in the discussion, sharing his perspective on how these interactions represent collaboration and not “influence” (as suggested in the original question).

Clinical Trials in Minnesota

12.13.13 | By

I walked away from Friday morning’s “Research in Your Backyard:  Pharmaceutical Clinical Trials in Minnesota” breakfast meeting in Minneapolis mightily impressed with two things: Frank Jaskulke’s very maroon and gold running shoes –a great contrast with the conservative suit the Minnesota life sciences thought leader was wearing – and what I learned about the work of the 

The Power of Modern Medicine

12.13.13 | By

Discovering and developing new treatments for the world’s most pressing health challenges helps inspire the work of innovators across the biopharmaceutical sector. More importantly, it’s our end-goal to ensure that patients around the world can obtain such innovative treatments in a timely manner.

Five points showing a brighter outlook for cancer patients

12.13.13 | By

It’s hard to see the silver lining when it comes to cancer, as many view the disease as a devastating prognosis. And while cancer can take a serious toll on patients and their loved ones, they should know that tremendous strides are being made in the research and development of new cancer medicines that are allowing patients to lead longer, healthier lives. Here are just a few reasons why cancer patients today should feel more hopeful:

Panel Discussion and New Report Highlight Benefit of Vermont Clinical Trials for Patients, State Economy

BURLINGTON, VT. (December 12, 2013) – Working with Vermont research institutions, including the University of Vermont and Fletcher Allen Health Care in Burlington, the nation's biopharmaceutical research companies have conducted 566 clinical trials of new medicines since 1999, according to a new report released today and highlighted at a panel discussion in Burlington. According to the latest data from 2011, clinical trials and other biopharmaceutical research conducted in the state generated $267 million in economic activity.

Fighting AIDS and other Infectious Diseases

12.12.13 | By

Recently the 26th Anniversary of World AIDS Day was celebrated, along with the remarkable progress that has been made against this disease.

Vermont Clinical Trials

12.12.13 | By

Between Lake Champlain and the Green Mountains of Vermont, the Burlington area houses one of the economic cores of the region.  Yesterday’s "Research in Your Backyard," event brought together researchers, doctors and patients, and focused on the biopharmaceutical industry’s contributions to the state’s prosperity through medical advances and breakthroughs in research. 

One Size Doesn't Fit All

12.11.13 | By

Over the weekend, the Washington Post ran a story about the price of prescription medicines offered through the Medicare Part B program, a benefit that provides coverage for outpatient administered medicines.

Pages

Subscribe to RSS - Opinion